MAY 25, 2016 08:00 AM PDT
Antibodies, Proteins and Peptides - Agilent's Approach to Make Complex Separations Simpler With More Resolution and Speed
SPONSORED BY: Agilent Genomics
CONTINUING EDUCATION (CME/CE/CEU) CREDITS: P.A.C.E. CE
10 32 4765

Speakers:
  • Application Scientist, Agilent Technologies
    Biography
      Dr. Suresh Babu C.V. completed his PhD in Biomolecular Science from Korea Institute of science and Technology, South Korea and did his Postdoctoral fellow at School of Medicine, University of Cincinnati, USA. He has presented various papers in international and national conferences, and has published more than 25 papers in reputed peer reviewed journals. He has an extensive experience in bioanalytical method development, validation and in interpretation of chromatogram, electropherogram and mass spectral data for biomolecule analysis. Currently he is working as Application Scientist at Agilent Technologies for past 7 years. His areas of interest in Biopharma include- LC, LC/MS, CE, CE-MS, electrophoresis, and mass spectrometry.
    • BioColumns Product Support & Applications Scientist, Agilent Technologies
      Biography
        Anne's work in analytical chemistry began at Saint Louis University where she received bachelors degrees in Chemistry and French. She then began her career in mass spectrometry at the University of Arizona where she received her Ph.D. under Dr. Vicki Wysocki, studying mass spectrometry and ion mobility as tools for structural determination of non-covalent protein assemblies. She joined Agilent in 2012, working as an application scientist on LC/QTOF and LC/IM/QTOF instrumentation specializing in metabolomics and lipidomics applications. In 2016 she moved into Agilent's bio-columns group, providing customer support for biological chromatography applications.

      Abstract:
      A quick look at the most recent new drug filings reveals how much interest there is in biologically derived molecules as therapeutic agents. The majority of the filings are for New Biological Entities rather than New Chemical Entities with the largest NBE group being Antibodies. As we move in this direction more and more data about the make up of these molecules, their degradation products, and improperly made versions are required. The need for this information about these complex systems makes efficient chromatographic separations very important to speeding up the development, quality control, and process monitoring of NBEs. 

      This presentation will look at new separation products designed to improve resolution and reproducibility in reverse phase separations. We will explore options for intact as well as reduced and digested proteins.

      For Research Use Only. Not for use in diagnostic procedures.

      Show Resources
      Loading Comments...